Novo Nordisk on Thursday launched an unsolicited bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to ...

Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity ...

Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can ...

Novo Nordisk's surprise bid for Metsera has set the stage for a high-stakes showdown in the obesity drug market, with Pfizer ...

A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U. obesity ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

A bidding war has broken into the open for the obesity-focused Metsera, with Novo Nordisk aiming to outbid Pfizer for the ...

The Danish pharma was rumored to be a bidder in the process to acquire Metsera earlier this year, which Pfizer ultimately won ...

Novo Nordisk raises its bid for obesity drugmaker Metsera to outmanoeuvre Pfizer, reshaping the fast-growing weight-loss ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...